Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
Yi-Long Lung Cancer Wu, Rafał Dziadziuszko, Jin Seok Ahn et al. · New England Journal of Medicine · 2024
Background Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK -positive non–small-cell lung cancer (NSCLC). Data on the efficacy and safety of adjuvant alectinib as compared with chemotherapy in patients with resected ALK -positive NSCLC are lacking. Methods We conducted a global, phase 3, open-label, randomized trial in which patients with completely resected, ALK -positive NSCLC of stage IB (tumors ≥4 cm), II, or IIIA (as classified according to the seventh edition of the Cancer Staging Manual of the American Joint Committee on Cancer and Union for International Cancer Control) were randomly assigned in a 1:1 ratio to receive oral alectinib (600 mg twice daily) for 24 months or intravenous platinum-based chemotherapy in four 21-day cycles. The primary end point was disease-free survival, tested hierarchically among patients with stage II or IIIA disease and then in the intention-to-treat population. Other end points included central nervous system (CNS) disease–free survival, overall survival, and safety. Research Summary Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer Results In total, 257 patients were randomly assigned to receive alectinib (130 patients) or chemotherapy (127 patients). The percentage of patients alive and disease-free at 2 years was 93.8% in the alectinib group and 63.0% in the chemotherapy group among patients with stage II or IIIA disease (hazard ratio for disease recurrence or death, 0.24; 95% confidence interval [CI], 0.13 to 0.45; P<0.001) and 93.6% and 63.7%, respectively, in the intention-to-treat population (hazard ratio, 0.24; 95% CI, 0.13 to 0.43; P<0.001). Alectinib was associated with a clinically meaningful benefit with respect to CNS disease–free survival as compared with chemotherapy (hazard ratio for CNS disease recurrence or death, 0.22; 95% CI, 0.08 to 0.58). Data for overall survival were immature. No unexpected safety findings were observed. Conclusions Among patients with resected ALK -positive NSCLC of stage IB, II, or IIIA, adjuvant alectinib significantly improved disease-free survival as compared with platinum-based chemotherapy. (Funded by F. Hoffmann–La Roche; ALINA ClinicalTrials.gov number, NCT03456076 .)
Cited by 431 works. doi:10.1056/nejmoa2310532 Open-access PDF
Authors
- Yi-Long Lung Cancer Wu
- Rafał Dziadziuszko
- Jin Seok Ahn
- Fabrice Barlési
- Makoto Nishio
- Ki Hyeong Lee
- Jong Seok Lee
- Wen‐Zhao Zhong
- Hidehito Horinouchi
- Weimin Mao
- Maximilian Johannes Hochmair
- Filippo de Marinis
- M.R. Migliorino
- Igor Bondarenko
- Shun Lü
- Qun Wang
- Tania Ochi Lohmann
- Tingting Xu
- Andrés Felipe Cardona
- Thorsten Ruf
References
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
- The National Comprehensive Cancer Network (NCCN).
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
- Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)